The CRISTALLO trial showed that venetoclax plus obinutuzumab achieved high minimal residual disease negativity as a frontline ...

TP53 mutations are found in approximately half of all cancers. Our co-founder, Dr. Arnold Levine, established the field of p53 biology when he discovered the p53 protein in 1979. Bringing together ...

Lung cancer cases are increasing in people who have never smoked, especially in women, a new study by the World Health Organization’s cancer agency has found.

In the subgroup with 17p deletion or TP53 mutation, zanubrutinib outperformed others with the most favorable HR (0.52) and the highest SUCRA value of 97%.

While genetic screening is not a magic bullet, it has the potential to change the landscape of childhood cancer care in India ...

By analyzing ERBB2 mRNA expression data, researchers identified a group of HER2-negative patients with poor outcomes and potential markers of treatment resistance.

In January 2025, Aptose announced the initiation of the TUSCANY trial and dosing in the first cohort of newly-diagnosed AML patients with the lowest starting dose (40 mg) of TUS as part of the ...

As direct target genes of HIF1α, USP22 and TP53 can be transcriptionally upregulated by HIF1α under hypoxic conditions. In TP53 wild-type HCC cells, HIF1α induced TP53-mediated inhibition of ...

Panel C shows the variant allele frequency of indicated DNMT3A and SOCS1 mutations in peripheral-blood ... CAR vector integration in TP53, or both to contribute to the development of CAR+ T ...

2 NHMRC Clinical Trials Centre University of Sydney, Sydney, New South Wales, Australia Objective To clarify the prognostic role of tumour protein 53 (TP53) mutations in patients with oesophageal ...

We propose that an extended analysis of all coding regions of the UBA1 gene may uncover other mutations with putative functional consequences. References [1]Beck DB, et al. Somatic Mutations in UBA1 ...